Storia in 1 fonti

Bernstein starts Summit with an Underperform, says ‘not on solid footing’

Bernstein analyst Jeffrey Walch initiated coverage of Summit Therapeutics (SMMT) with an Underperform rating and $7.70 price target The firm re...

Raccontata da